Maplirpacept

美帕西普

Report date: 2026/05/07 20:00:36

Base Information

Drug NameMaplirpacept
Drug Alias NameTTI-622PF-07901801
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionCluster of differentiation 47 inhibitors
TargetsCluster of differentiation 47
Therapy Area/IndicationsPrimary mediastinal B cell lymphomaFallopian Tube NeoplasmsSkin Neoplasms +[15] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesIsraelSouth Korea +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesTrillium Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesTrillium Therapeutics IncPfizer IncNational Cancer Institute +[4] 
Inactive CompaniesN/A
Active IndicationsPrimary mediastinal B cell lymphomaSkin NeoplasmsHematologic Neoplasms +[10] 
Inactive IndicationsFallopian Tube NeoplasmsOvarian NeoplasmsPeritoneal Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksN/A